Compare ADMA Biologics Inc (ADMA) vs Centrus Energy Corp (LEU) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Centrus Energy (LEU) trades at $174.23, up 7.46% today, with mixed technical signals showing neutral momentum. The company reported strong Q1 2026 earnings beat but faces valuation concerns with a P/E of 63.36. Recent catalysts include a $900 million DOE contract and inclusion in the S&P SmallCap 600 index, positioning LEU as the sole U.S.-licensed HALEU producer amid growing nuclear energy demand.

LEU offers exposure to U.S. nuclear fuel supply chain growth with $3.9 billion contracted backlog, but high valuation and execution risks warrant caution. Analyst consensus targets $219.50 (26% upside) with no sell ratings, though recent earnings misses and declining 2026 profit margins highlight operational challenges. The stock's premium valuation requires sustained contract execution and margin improvement to justify current levels.